Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.

about

Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.

Item

http://www.wikidata.org/entity/Q53814762

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Levels of interleukin-1 beta c ...... of tocilizumab therapy) study.

@en

Levels of interleukin-1 beta c ...... eumatoid arthritis: the PETITE

@nl

type

Item

label

Levels of interleukin-1 beta c ...... of tocilizumab therapy) study.

@en

Levels of interleukin-1 beta c ...... eumatoid arthritis: the PETITE

@nl

prefLabel

Levels of interleukin-1 beta c ...... of tocilizumab therapy) study.

@en

Levels of interleukin-1 beta c ...... eumatoid arthritis: the PETITE

@nl

P1476

Levels of interleukin-1 beta c ...... of tocilizumab therapy) study.

@en

P2093

Hiroaki Nakamura

http://www.w3.org/2001/XMLSchema#string

Kenji Mamoto

http://www.w3.org/2001/XMLSchema#string

Kentaro Inui

http://www.w3.org/2001/XMLSchema#string

Masahiro Tada

http://www.w3.org/2001/XMLSchema#string

Shigeyuki Wakitani

http://www.w3.org/2001/XMLSchema#string

Tadashi Okano

http://www.w3.org/2001/XMLSchema#string

Tatsuya Koike

http://www.w3.org/2001/XMLSchema#string

Yuko Sugioka

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Anti-cytokine therapy for rheumatoid arthritis.

D-dimer antigen: current concepts and future prospects.

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

P2888

s00296-015-3379-x

P304

349-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00296-015-3379-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26438386

http://www.w3.org/2001/XMLSchema#string

P921

interleukin